0Suppliers
3Customers
1Debt Items
16Related Chains

Arcturus Therapeutics Holdings Inc. Suppliers

No suppliers on recordArcturus Therapeutics Holdings Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Arcturus Therapeutics Holdings Inc. Customers

TickerNameConfidenceEvidence
CSL-SEQIRUS CSL-SEQIRUS 92% In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer.
BARDA BARDA 90% The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 (IAS 20), Accounting for Government Grants and Disclosure …
GATES-FOUNDATION GATES-FOUNDATION 85% The Company recognized $ 0.6 million of grant revenue related to cost reimbursement under two grants awarded by the Gates Foundation.

Arcturus Therapeutics Holdings Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ARCT-DEBT Debt stack $24.0M 90% Market cache reports total debt of $24.0M.

Arcturus Therapeutics Holdings Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Arcturus Therapeutics Holdings Inc..

Arcturus Therapeutics Holdings Inc. Ownership

HolderNameConfidenceEvidence
ARCT-OWNER-FEDERATED-HERMES-INC FEDERATED HERMES, INC. 90% 13F overlay lists FEDERATED HERMES, INC. as top holder; 127 tracked holders.

Arcturus Therapeutics Holdings Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SNYNF Sanofi 100.00 2
VRTX Vertex Pharmaceuticals Incorporated 100.00 2
LLY Eli Lilly and Company 100.00 2
KOD Kodiak Sciences Inc. 100.00 2
KLRS Kalaris Therapeutics, Inc. 100.00 2
TVTX Travere Therapeutics, Inc. 100.00 2
MGTX MeiraGTx Holdings plc 100.00 2
JNJ Johnson & Johnson 100.00 2
BARDA BARDA 60.75 1 ['receiving']
CSLLY CSL Limited 51.30 1 ['receiving']
RCEL AVITA Medical, Inc. 50.00 2
IMRN Immuron Limited 50.00 2
VXRT Vaxart, Inc. 50.00 2
RGNX REGENXBIO Inc. 50.00 2
HAE Haemonetics Corporation 50.00 2
FDMT 4D Molecular Therapeutics, Inc. 36.29 1 ['spend']